These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20432461)

  • 41. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications.
    Miyahara N; Shoda J; Ishige K; Kawamoto T; Ueda T; Taki R; Ohkohchi N; Hyodo I; Thomas MB; Krishnamurthy S; Carraway KL; Irimura T
    Eur J Cancer; 2008 May; 44(7):1048-56. PubMed ID: 18397823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W; Liu LH; Ho P; Spector NL
    Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive.
    Carraway KL; Perez A; Idris N; Jepson S; Arango M; Komatsu M; Haq B; Price-Schiavi SA; Zhang J; Carraway CA
    Prog Nucleic Acid Res Mol Biol; 2002; 71():149-85. PubMed ID: 12102554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Rowson-Hodel AR; Wald JH; Hatakeyama J; O'Neal WK; Stonebraker JR; VanderVorst K; Saldana MJ; Borowsky AD; Sweeney C; Carraway KL
    Oncogene; 2018 Jan; 37(2):197-207. PubMed ID: 28892049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Muc4/sialomucin complex in the mammary gland and breast cancer.
    Carraway KL; Price-Schiavi SA; Komatsu M; Jepson S; Perez A; Carraway CA
    J Mammary Gland Biol Neoplasia; 2001 Jul; 6(3):323-37. PubMed ID: 11547901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of integrin alpha(6)beta(4) with ErbB3 and implication in heregulin-induced ErbB3/ErbB2-mediated DNA synthesis.
    Kawano S; Mizutani K; Miyata M; Ikeda W; Takai Y
    Genes Cells; 2010 Sep; 15(9):995-1001. PubMed ID: 20695903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer.
    Senapati S; Chaturvedi P; Sharma P; Venkatraman G; Meza JL; El-Rifai W; Roy HK; Batra SK
    Br J Cancer; 2008 Sep; 99(6):949-56. PubMed ID: 18781152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
    Huang X; Gao L; Wang S; McManaman JL; Thor AD; Yang X; Esteva FJ; Liu B
    Cancer Res; 2010 Feb; 70(3):1204-14. PubMed ID: 20103628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
    Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
    J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis.
    Carraway CA; Carraway KL
    Sci STKE; 2007 Apr; 2007(381):re3. PubMed ID: 17426346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line.
    Yoo JY; Hamburger AW
    Mol Cell Endocrinol; 1998 Mar; 138(1-2):163-71. PubMed ID: 9685225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.
    Steinkamp MP; Low-Nam ST; Yang S; Lidke KA; Lidke DS; Wilson BS
    Mol Cell Biol; 2014 Mar; 34(6):965-77. PubMed ID: 24379439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
    Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
    J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
    Price-Schiavi SA; Andrechek E; Idris N; Li P; Rong M; Zhang J; Carothers Carraway CA; Muller WJ; Carraway KL
    J Cell Physiol; 2005 Apr; 203(1):44-53. PubMed ID: 15499570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduction of the ST6 β-galactosamide α-2,6-sialyltransferase 1 (ST6GAL1)-catalyzed sialylation of nectin-like molecule 2/cell adhesion molecule 1 and enhancement of ErbB2/ErbB3 signaling by microRNA-199a.
    Minami A; Shimono Y; Mizutani K; Nobutani K; Momose K; Azuma T; Takai Y
    J Biol Chem; 2013 Apr; 288(17):11845-53. PubMed ID: 23504322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and differential signaling of heregulins in pancreatic cancer cells.
    Kolb A; Kleeff J; Arnold N; Giese NA; Giese T; Korc M; Friess H
    Int J Cancer; 2007 Feb; 120(3):514-23. PubMed ID: 17096356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.